Abstract
Personalized medicine simply means the prescription of specific treatments and therapeutics best suited for an individual (Jain 2009). It is also referred to as individualized or individual-based therapy. Personalized medicine is based on the idea of using a patient’s genotype as a factor in deciding on the treatment options, but other factors are also taken into consideration. Genomic/proteomic technologies have facilitated the development of personalized medicines but other technologies are also contributing to this effort. Application of the principles of personalized medicine to management of cardiovascular diseases is referred to as “personalized cardiology.”
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genetics 2006;38:644–51.
Caulfield T, McGuire AL, Cho M, et al. Research Ethics Recommendations for Whole-Genome Research: Consensus Statement. PLoS Biology 2008;6:e73 doi:10.1371/journal.pbio.0060073.
Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004;291:2821–7.
Couvert P, Giral P, Dejager S, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008;9:1217–27.
Ferrandi M, Molinari I, Torielli L, et al. Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 1: Experimental Studies. Sci Transl Med 2010;2:59ra86.
Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial. JAMA 2005;293:2245–2256.
Harrap SB. Where are all the blood-pressure genes? Lancet 2003;361:2149–51.
Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008;51:435–43.
Jain KK. Textbook of Personalized Medicine. Springer, New York, 2009.
Jain KK. Personalized Medicine: scientific & commercial aspects. Jain PharmaBiotech, Basel, Switzerland, 2011.
Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009;157:442–9.
Judson R, Brain C, Dain B, et al. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004;177:345–51.
Kathiresan S, Melander O, Anevski D, et al. Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events. NEJM 2008;358:1240–1249.
Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110:1903–8.
Kunnas TA, Ilveskoski E, Niskakangas T, et al. Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 2002a;80:605–9.
Kunnas TA, Lehtimaki T, Laaksonen R, et al. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med 2002b;80:802–7.
Lanzani C, Citterio L, Glorioso N, et al. Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 2: Clinical Studies. Sci Transl Med 2010; 2:59ra87.
Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. PNAS 2006;103:11288–93.
Ordovas JM, Shen H. Pharmacogenetics of Lipid-lowering Therapies. Curr Atheroscler Rep 2002;4:183–92.
Polisecki E, Muallem H, Maeda N, et al; on behalf of the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008;200:109–14.
Romanoski CE, Lee S, Kim MJ, et al. Systems Genetics Analysis of Gene-by-Environment Interactions in Human Cells. Amer J Hum Genet 2010;86:399–410.
Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537–41.
Shiffman D, Chasman DI, Zee RY, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women’s Health Study. J Am Coll Cardiol 2008;51:444–8.
Siest G, Marteau JB, Maumus S, et al. Pharmacogenomics and pharmacoproteomics: a strategy for cardio-vascular drugs. Ann Pharm Fr 2007;65:203–10.
Taylor AL, Ziesche S, Yancy C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. NEJM 2004;351:2049–2057.
Terra SG, Pauly DF, Lee CR, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005;77:127–37.
Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004;4:247–55.
Voora D, Shah SH, Reed CR, et al. Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response. Circulation: Cardiovascular Genetics 2008;1:100–106.
Wickline SA, Neubauer AM, Winter P, et al. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2006;26:435–41.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2011). Personalized Cardiology. In: Applications of Biotechnology in Cardiovascular Therapeutics. Humana Press. https://doi.org/10.1007/978-1-61779-240-3_10
Download citation
DOI: https://doi.org/10.1007/978-1-61779-240-3_10
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-239-7
Online ISBN: 978-1-61779-240-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)